Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Takeda farms out cancer drug alisertib to Puma Biotech | pharmaphorum
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma pounces on failed Takeda drug, snapping up cancer prospect
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
5 Best Biotech Stocks for 2018 | InvestorPlace
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
